Small Caps Dashboard
 

CYCLOPHARM


Sector: Medical technology

Industry: Radiology services

This Australian med tech pioneer reminds us in many ways of one of our best recommendations in the sector, Medical Developments, which has delivered more than five-fold on our original investment. Cyclopharm is positioned to grow its market substantially if it gains approval for sales into the US market. Its product Technegas has generated revenues in 57 countries. Over 195k patient procedures in 2018, 4.2m patient procedures since 1986. With 1,600 Technegas generators sold globally, CYC’s underlying business is profitable and supports a small dividend.

There are at least 3m cases of Pulmonary Embolism globally each year. The company sells Technegas generators to radiology departments, and, on a recurring basis, the raw material (TN-99) in the form of 50 dose Patient Administration Sets (PAS). The Technegas generator turns each dose into a gas which is inhaled for just 3 or 4 breaths to provide the diagnostic rebound material that delivers a quality 3-D image to diagnose PE, with fewer risks and lower infrastructure needs than existing CT diagnostics.

**FY21 Forecast
 

See our recomndations.
Unlock

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Donec porttitor semper molestie. Ut eleifend, erat eu pulvinar iaculis, odio nunc venenatis tellus, ut placerat lorem purus sed tellus. Duis ut leo vitae massa facilisis dictum sed a dui. Proin quis pulvinar purus, vestibulum lobortis justo.

 
  • Radar Rating Unlock
  • Market Cap ($m)* 158.8
  • Dividend Yield (%)* 0.6
  • NET CASH ($M) 30
  • * Data as of 29 July 2021

Latest Research Summary

CYCLOPHARM: RESEARCH TIP UPDATE - JUNE 2021
03 Jun, 2021

Orci varius natoque penatibus et magnis dis parturient montes, nascetur ridiculus mus. Maecenas ut ex et est semper fringilla. Nam et lectus augue. Integer non consectetur ligula. Maecenas tortor metus, molestie at aliquam sit amet, feugiat sed ipsum. Donec vehicula mi ac neque tempor dignissim.

Unlock to view the latest research

Previous Research

Research Date Radar Rating  
CYCLOPHARM: RESEARCH TIP UPDATE - JUNE 2021 03 Jun, 2021 0f2a8f7a View Research
CYCLOPHARM : RESEARCH TIP UPDATES - FEBRUARY 2021 04 Feb, 2021 c1f85198 View Research
CYCLOPHARM: RESEARCH TIP UPDATES - OCTOBER 2020 01 Oct, 2020 a292b403 View Research
CYCLOPHARM: RESEARCH TIP UPDATE - JULY 2020 02 Jul, 2020 f198ee87 View Research
CYCLOPHARM: RESEARCH TIP UPDATE - MAY 2020 28 May, 2020 d6fac6ba View Research
CYCLOPHARM: RESEARCH TIP UPDATE - 1H20 REPORTING SEASON 12 Mar, 2020 abb00ef5 View Research
CYCLOPHARM: RESEARCH TIP UPDATE - NOVEMBER 2019 14 Nov, 2019 4d9351ef View Research
CYCLOPHARM: RESEARCH TIP UPDATES - JUNE 2019 26 Jun, 2019 7c7e3910 View Research
CYCLOPHARM: RESEARCH TIP UPDATES - MAY 2019 15 May, 2019 3cfa5627 View Research
CYCLOPHARM: RESEARCH TIP UPDATES - JANUARY 2019 30 Jan, 2019 3a3da61c View Research
CYCLOPHARM: RESEARCH TIP UPDATES - JANUARY 2019 16 Jan, 2019 7471258a View Research
CYCLOPHARM: RESEARCH TIP - NOVEMBER 2018 21 Nov, 2018 7f0c1b3f View Research